MBMegan Ball

Megan Ball

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Megan Ball has a total of 39 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Antenatal Presentation of MRPS22 ‐Related Mitochondrial Disease Confirmed With Rapid Proteomics

    by Liana N. Semcesen, Megan Ball, Daniella H. Hock, Juliet Kaye, Aimee Woods, Lucas De Jong, MitoMDT Diagnostic Network for Genomics and Omics, John Christodoulou, David R. Thorburn, Alison G. Compton, et al.

    MRPS22 ‐related mitochondrial disease (MIM#611719) is a rare autosomal recessive disorder caused by defects in the mitochondrial ribosomal protein S22, a component of the small mitoribosomal subunit essential for mitochondrial translation. Of the few reported cases, most present antenatally with a severe phenotype, conveying a poor prognosis. We describe a fetus with severe antenatal‐onset MRPS22 ‐related mitochondrial disease and the use of multi‐omics in the molecular diagnosis. A primigravida underwent termination of pregnancy following identification of multiple congenital anomalies (hydrops fetalis, microcephaly, corpus callosal agenesis, periventricular cysts and cardiac hypertrophy) on ultrasound at 20 + 2 weeks' gestation, confirmed on fetal magnetic resonance imaging. Trio genome sequencing revealed compound heterozygous variants in MRPS22 (NM_020191.4: c.509G>A; p.(Arg170His) and c.565C>G; p.(Arg189Gly)). Rapid proteomic analysis demonstrated destabilisation of the small mitoribosomal subunit and combined reduction of OXPHOS complexes, supporting the pathogenicity of the variants. This case consolidates the antenatal phenotype of severe MRPS22‐related disease and highlights the importance of considering mitochondrial disease in the differential diagnosis of congenital anomalies, especially hydrops fetalis and corpus callosum anomalies. This study provides evidence for the utility of multi‐omic approaches (trio genome sequencing, proteomics) in confirming variant pathogenicity following pregnancy loss, enabling accurate diagnosis, and informing reproductive counselling for affected families.

  • Open Access

    Mainstreaming genomic testing for mitochondrial disease in Australia

    by Megan Ball, Naomi Baker, Sze Chern Lim, Sarah Casauria, Sebastian Lunke, Alison G. Compton, David R. Thorburn, John Christodoulou, Zornitza Stark

    Genomic sequencing has transformed the diagnostic approach for mitochondrial disease, yet integration into standard clinical practice is limited by access and funding. We conducted a post-implementation evaluation of genome sequencing (GS) for mitochondrial disease in Australia, which became publicly funded through the Medicare Benefits Scheme (MBS) in November 2023, to allow for broader access to testing. Test request data, including demographics, phenotypic information, and the diagnostic outcomes, were collected from November 2023 to May 2025 from the Victorian Clinical Genetics Services, the current laboratory provider of the MBS-funded service. Test uptake was 26% of predicted, with lower test rates in regional and remote areas. Over the first 19 months, 300 individuals suspected of mitochondrial disease underwent GS with a median turnaround time of 84 days (8 days–218 days). The diagnostic yield was 20%, with 56% of diagnoses in known mitochondrial disease genes. Of these, 70% (24 of 34) were in mitochondrial DNA. Seventeen diagnoses were in individuals who had prior non-diagnostic testing (exome sequencing or gene panel). We demonstrate that publicly-funded GS can deliver meaningful diagnostic outcomes for mitochondrial disease on a national scale. To maximise its impact, attention must now shift towards ensuring equitable access, particularly for regional and remote areas, and embedding sustainable mainstreaming models that support both genetic and non-genetic clinicians.


  • Open Access

    Therapies for Mitochondrial Disease: Past, Present, and Future

    by Megan Ball, Nicole J. van Bergen, Alison G. Compton, David R. Thorburn, Shamima Rahman, John Christodoulou

    Mitochondrial disease is a diverse group of clinically and genetically complex disorders caused by pathogenic variants in nuclear or mitochondrial DNA‐encoded genes that disrupt mitochondrial energy production or other important mitochondrial pathways. Mitochondrial disease can present with a wide spectrum of clinical features and can often be difficult to recognize. These conditions can be devastating; however, for the majority, there is no targeted treatment. In the last 60 years, mitochondrial medicine has experienced significant evolution, moving from the pre‐molecular era to the Age of Genomics in which considerable gene discovery and advancement in our understanding of the pathophysiology of mitochondrial disease have been made. In the last decade, in response to the urgent need for effective treatments, a wide range of emerging therapies have been developed, driven by innovative approaches addressing both the genetic and cellular mechanisms underpinning the diseases. Emerging therapies include dietary intervention, small molecule therapies aimed to restore mitochondrial function, stem cell or liver transplantation, and gene or RNA‐based therapies. However, despite these advances, translation to clinical practice is complicated by the sheer genetic and clinical complexity of mitochondrial disease, difficulty in efficient and precise delivery of therapies to affected tissues, rarity of individual genetic conditions, lack of reliable biomarkers and clinically relevant outcome measures, and the dearth of natural history data. This review examines the latest developments in the pursuit to identify effective treatments for mitochondrial disease and discusses the barriers impeding their success in translation to clinical practice. While treatment for mitochondrial disease may be on the horizon, many challenges must be addressed before it can become a reality.


  • Critically unwell infants and children with mitochondrial disorders diagnosed by ultrarapid genomic sequencing

    by Megan Ball, Sophie E. Bouffler, Christopher B. Barnett, Mary-Louise Freckmann, Matthew F. Hunter, Benjamin Kamien, Karin S. Kassahn, Sebastian Lunke, Chirag V. Patel, Jason Pinner, et al.


  • Impact of initial flow rate of high‐flow nasal cannula on clinical outcomes in infants with bronchiolitis

    by Megan Ball, Cathie Hilditch, Garth A Hargreaves, David Baulderstone

    Aim: Bronchiolitis is a common condition in the paediatric population. Severe cases often receive respiratory support with high‐flow nasal cannula (HFNC). Significant variation in the application of HFNC exists throughout Australia and internationally. This study aimed to determine if the flow rate used initially and when ceasing HFNC at the end of the illness alters clinical outcomes.Methods: A retrospective analysis was conducted of 251 children less than 12 months of age when admitted to the Women's and Children's Hospital Adelaide with bronchiolitis requiring HFNC therapy between the period of April 2016 to April 2019. The primary outcome was to determine if commencing HFNC therapy at different rates (1 L/kg/min, 1.5 L/kg/min and 2 L/kg/min) affected length of stay or treatment failure (escalation in physiological parameters or respiratory support).Results: Treatment failure occurred in 33%, 13% and 26% of those starting at 1 L/kg/min, 1.5 L/kg/min and 2 L/kg/min, respectively. Commencing HFNC therapy at 1 L/kg/min increased length of stay by an average of 30 h (P < 0.001) and the likelihood of treatment failure (P < 0.002) compared with starting at 1.5 L/kg/min. There was no statistical difference in outcomes between starting at 1.5 L/kg/min and 2 L/kg/min. There was no significant difference in the length of stay from the starting of weaning HFNC to time of discharge.Conclusions: The commencing flow rates of initial HFNC therapy impact individual patient's outcomes, including length of stay and rates of treatment failure. Clinicians should consider commencing HFNC at 1.5 L/kg/min or 2 L/kg/min in infants that have failed low‐flow oxygen therapy.